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Background: Inflammation has an important role in cancer survival, yet whether serum markers of
inflammation predict response to potentially curative neoadjuvant chemotherapy (NAC) in oesophageal
adenocarcinoma (OAC) is controversial. This study aimed to determine whether the systemic inflamma-
tory response (SIR) is associated with response to NAC and survival.
Methods: Consecutive patients with OAC planned for surgery with curative intent received blood
neutrophil and lymphocyte measurements at diagnosis to calculate the neutrophil to lymphocyte ratio
(NLR). Pathological variables including pTNM stage, differentiation, vascular invasion and Mandard
tumour regression grade (TRG) were recorded. TRGs 1 and 2 were taken to represent a good response,
and the primary outcome was overall survival.
Results: During follow-up of 136 patients, 36 patients (26⋅5 per cent) had recurrence and 69 (50⋅7 per
cent) died. Receiver operating characteristic (ROC) curve analysis of NLR before NAC predicted poor
TRG (area under the ROC curve 0⋅71, 95 per cent c.i. 0⋅58 to 0⋅83; P = 0⋅002). In univariable analysis,
pT category (P<0⋅001), pN category (P< 0⋅001), poor differentiation (P = 0⋅006), margin positivity
(P = 0⋅001), poor TRG (P = 0⋅014) and NLR (dichotomized at 2⋅25; P = 0⋅017) were associated with
poor overall survival, and NLR retained independent significance in multivariable analysis (hazard ratio
2⋅26, 95 per cent c.i. 1⋅03 to 4⋅93; P = 0⋅042).
Conclusion: The pretreatment NLR was associated with a pathological response to NAC and overall
survival in patients with OAC.
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Introduction
In the West, most patients who are offered attempted
curative therapy for oesophageal adenocarcinoma
(OAC) will undergo a multimodal treatment involving
either neoadjuvant chemotherapy (NAC) followed by
surgery1, perioperative chemotherapy2, or neoadjuvant
chemoradiotherapy3. Despite evidence of survival benefit,
a meta-analysis4 comparing NAC with surgery alone in
2062 patients found only a 5⋅1 per cent absolute 2-year
survival advantage after NAC, because only a small minor-
ity experienced a significant pathological response. In a
multicentre cohort study5, a clinically meaningful local
response to NAC was restricted to the 14⋅8 per cent of
patients with a tumour regression grade (TRG) of 1–2.
Inflammation is now widely recognized as a feature of
many cancers6. Among a variety of inflammatory markers,
derivative biomarkers – neutrophil to lymphocyte ratio
(NLR), platelet to lymphocyte ratio (PLR), neutrophil to
platelet score, and the modified Glasgow Prognostic Score
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(mGPS) – have been reported to be associated with poor
survival7–9.
The aim of this study was to determine whether clin-
ically readily available serum markers of inflammation
obtained from routinely performed patient screening
blood profiles might predict response to potentially
curative NAC in OAC, and whether there was a subse-
quent relationship with survival after potentially curative
oesophagectomy.
Methods
To test the proposed hypotheses, a single cohort of
patients diagnosed with OAC between 1 January 2010 and
31 August 2018 was recruited, and included patients with
radiological TNM stage I–III deemed amenable to treat-
ment with curative intent. All patients were managed by a
multidisciplinary specialist team (MDT) with an interest
in oesophageal cancer, including clinical nurse specialists,
gastroenterologists, surgeons, oncologists, radiologists,
anaesthetists and pathologists10. Management plans were
individually tailored according to both patient and disease
factors. Staging was done by means of CT, endoscopic
ultrasonography, CT–PET and staging laparoscopy as
appropriate. The South-East Wales MDT treatment algo-
rithms for oesophageal carcinoma have been described
previously11–13.
The majority of patients received two cycles of cisplatin
80mg/m2 and 5-fluorouracil 1000mg/m2 for 4 days. A
minority received three cycles of epirubicin 50mg/m2,
cisplatin 60mg/m2 and 5-fluorouracil 200mg/m2 or
capecitabine 625mg/m2 (ECF/X regimen). Definitive
chemoradiotherapy was offered to patients with localized
squamous cell carcinoma and those with adenocarcinoma
deemed unsuitable for surgery because of disease extent
and/or medical co-morbidity14,15.
The standard surgical approach was subtotal transthor-
acic oesophagectomy (TTO), as described by Lewis16
and Tanner17. Transhiatal oesophagectomy (THO), as
described by Orringer18, was used selectively in patients
with adenocarcinoma of the lower third of the oesopha-
gus who had significant cardiorespiratory co-morbidity,
cT1–3N0 disease. A modified extended D2 lymphadenec-
tomy (preserving the pancreas and spleen where possible)
was performed.
Ethical approval was sought, but the chair of the Cardiff
and Vale University Health Board ethics committee con-
firmed that individual patient consent was not required to
report clinical outcomes alone, and no formal approval was
necessary.
Table 1 Clinicopathological patient factors
No. of patients (n = 136)
Age (years)
<65 46 (33⋅8)
66–75 68 (50⋅0)
>75 22 (16⋅2)
Sex ratio (F :M) 30 : 106
Operative approach n = 113
TTO 71 (62⋅8)
THO 42 (37⋅2)
Neutrophil : lymphocyte ratio
<2⋅25 36 (26⋅5)
≥2⋅25 100 (73⋅5)
pT category
pT0 11 (8⋅1)
pT1 10 (7⋅4)
pT2 10 (7⋅4)
pT3 69 (50⋅7)
pT4 13 (9⋅6)
No resection 23 (16⋅9)
pN category
pN0 35 (25⋅7)
pN1 34 (25⋅0)
pN2 26 (19⋅1)
pN3 18 (13⋅2)
No resection 23 (16⋅9)
Mandard TRG
Good 23 (16⋅9)
Poor 113 (83⋅1)
Differentiation
Well or moderate 64 (47⋅1)
Poor 72 (52⋅9)
CRM
Negative 58 (42⋅6)
Positive 55 (40⋅4)
No resection 23 (16⋅9)
Lymph node yield n = 113
<15 43 (38⋅1)
≥15 70 (61⋅9)
Values in parentheses are percentages. TTO, transthoracic oesophagec-
tomy; THO, transhiatal oesophagectomy; TRG, tumour regression grade;
CRM, circumferential resection margin.
Clinicopathological characteristics
Tumours were staged using the seventh edition of the
AJCC/UICC TNM staging system. Pathological factors
were recorded from pathology reports issued at the time
of surgery, and included tumour differentiation, margin
status and the number of lymph nodes with and without
metastasis. The TRG was quantified using the Mandard
system19 by a histopathologist with a special interest in
oesophagogastric cancer. Briefly, Mandard TRGs range
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Table 2 Association between pretreatment markers of systemic inflammatory response and poor Mandard tumour regression grade
No. of patients with marker level† ROC analysis
Concentration* Low* Normal High AUC P
Haemoglobin (g/l) 138 (128–148) 33 103 0 0⋅47 (0⋅33, 0⋅62) 0⋅699
White cell count (×109/l) 7⋅6 (6⋅2–8⋅1) 2 124 10 0⋅59 (0⋅46, 0⋅72) 0⋅158
Neutrophil count (×109/l) 5⋅0 (3⋅9–6⋅1) 2 118 16 0⋅68 (0⋅56, 0⋅80) 0⋅008
Lymphocyte count (×109/l) 1⋅7 (1⋅3–2⋅1) 8 123 5 0⋅40 (0⋅25, 0⋅54) 0⋅115
Platelet count (×109/l) 281 (233–330) 3 123 10 0⋅52 (0⋅40, 0⋅65) 0⋅691
Neutrophil to lymphocyte ratio 3⋅00 (2⋅15–3⋅89) 0⋅71 (0⋅58, 0⋅83) 0⋅002
Platelet to lymphocyte ratio 160 (122–198) 0⋅66 (0⋅52, 0⋅79) 0⋅019
Values in parentheses are 95 per cent confidence intervals unless indicated otherwise; *values are median (i.q.r.). †Based on local thresholds. AUC, area
under the receiver operating characteristic (ROC) curve.
Fig. 1 Receiver operating characteristic (ROC) curve analy-
sis of neutrophil to lymphocyte ratio and Mandard tumour
response grade
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Area under the ROC curve (AUC) = 0⋅71 (95 per cent c.i. 0⋅58 to 0⋅83;
P = 0⋅002).
from 1 to 5, based on the ratio of fibrosis to viable can-
cerous cells5,19. In keeping with the Oesophageal Cancer
Clinical And Molecular Stratification (OCCAMS) report-
ing methodology, TRGs of 1 and 2 were considered
to constitute good response, with TRGs of 3, 4 and 5
constituting poor response5.
Routine laboratory measurements of haemoglobin,
whole white cell count, neutrophil, lymphocyte and
platelet counts at the time of diagnosis were recorded.
Derivate measurements of systemic inflammation were
constructed by calculating the NLR and PLR7,20.
Patients were followed up at regular intervals of 3months
in the first year and 6months thereafter. In the event that
patients developed symptoms suggestive of recurrent dis-
ease, investigations were undertaken sooner. Follow-up
surveillance was conducted for 5 years or until death,
whichever was sooner. Overall survival was calculated
from time of diagnosis to the date of death or censor-
ing. Disease-free survival was measured from the date of
surgery to the date of recurrence or censoring. The time of
recurrence was taken as the date of the confirmatory inves-
tigation, on an intention-to-treat basis. Death certification
was obtained from the Office for National Statistics via the
Cancer Network Information System Cymru.
Statistical analysis
Grouped data were expressed as median (i.q.r.) values,
and non-parametric methodology was used throughout.
Receiver operating characteristic (ROC) curve analysis was
employed to assess the predictive value of continuous vari-
ables with the primary outcomemeasure. ROC analysis was
also used to determine dichotomization thresholds for poor
Mandard TRGs, as described by Youden21. Univariable
and multivariable logistical regression analysis was used to
identify independent associations of categorical variables
with poor Mandard TRGs. Variables with P < 0⋅100 were
included in the model using backward conditional method-
ology. Patient demographics were analysed between the
treatment modalities by means of χ2 or non-parametric
tests, including the Mann–Whitney U test. These tests
were also employed in the analysis of disease recurrence
and time to recurrence for the treatment groups.
Overall survival was measured from the date of diagno-
sis, and disease-free survival from date of surgery. This
approach was adopted in the randomized trials to allow for
the variable interval to surgery after diagnosis, depending
on whether NAC was prescribed22. As in the trials, events
resulting in a failure to complete curative treatment, such
as not proceeding to surgery, open and close laparotomy,
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Table 3 Logistic regression analysis of preoperative factors associated with poor Mandard tumour regression grade
Univariable analysis Multivariable analysis
Odds ratio P Odds ratio P
Age (<65 versus 66–75 versus>75 years) 1⋅11 (0⋅58, 2⋅15) 0⋅753
Sex (F versus M) 1⋅31 (0⋅47, 3⋅68) 0⋅610
Differentiation (well/moderate versus poor) 17⋅09 (3⋅82, 76⋅55) <0⋅001 15⋅92 (3⋅42, 74⋅02) <0⋅001
cTNM (1 versus 2 versus 3 versus 4) 1⋅38 (0⋅76, 2⋅48) 0⋅289
Neutrophil to lymphocyte ratio (<2⋅25 versus≥2⋅25) 6⋅43 (2⋅47, 16⋅77) <0⋅001 5⋅86 (2⋅03, 16⋅92) 0⋅001
Values in parentheses are 95 per cent confidence intervals.
Table 4 Cox proportional hazards analysis of factors associated with overall survival
Univariable analysis Multivariable analysis
Hazard ratio P Hazard ratio P
Age (<65 versus 66–75 versus>75 years) 0⋅87 (0⋅58, 1⋅30) 0⋅494
Sex (F versus M) 1⋅13 (0⋅57, 2⋅21) 0⋅731
Operative approach (TTO versus THO) 1⋅25 (0⋅69, 2⋅24) 0⋅462
Neutrophil to lymphocyte ratio (<2⋅25 versus≥2⋅25) 2⋅33 (1⋅16, 4⋅68) 0⋅017 2⋅26 (1⋅03, 4⋅93) 0⋅042
pT category (0 versus 1 versus 2 versus 3 versus 4) 2⋅14 (1⋅43, 3⋅21) <0⋅001 1⋅81 (1⋅06, 3⋅08) 0⋅029
pN category (0 versus 1 versus 2 versus 3) 1⋅70 (1⋅34, 2⋅15) <0⋅001 1⋅57 (1⋅14, 2⋅17) 0⋅006
Mandard TRG (good versus poor) 2⋅67 (1⋅22, 5⋅86) 0⋅014 4⋅28 (1⋅37, 13⋅34) 0⋅012
Differentiation (well/moderate versus poor) 2⋅26 (1⋅27, 4⋅02) 0⋅006 2⋅71 (1⋅39, 5⋅29) 0⋅004
CRM (negative versus positive) 2⋅46 (1⋅43, 4⋅22) 0⋅001 0⋅171
Lymph node yield (<15 versus≥15) 0⋅75 (0⋅43, 1⋅31) 0⋅306
Values in parentheses are 95 per cent confidence intervals. TTO, transthoracic oesophagectomy; THO, transhiatal oesophagectomy; TRG, tumour
regression grade; CRM, circumferential resection margin.
palliative resection and in-hospital mortality, were assumed
to have occurred at this landmark time, in order tomaintain
the intention-to-treat analysis. Cumulative survival was
calculated according to the Kaplan–Meier method, with
differences between groups analysed using the log rank
test. A univariable analysis examining factors influencing
survival was performed initially by the life-table method of
Kaplan and Meier, and factors with associations found to
be significant at the P < 0⋅010 level were retained in a Cox
proportional hazards model using backward conditional
methodology to assess the prognostic value of individual
variables.
All statistical analysis was performed in SPSS® Statis-
tics v25.0.0.0 (IBM, Armonk, New York, USA) with
extension R.
Results
A total of 136 patients with OAC were identified and
underwent surgery after NAC; the operative approach
was open in 120 patients with 16 patients undergoing
laparoscopically assisted surgery. Details of patients’
clinicopathological factors can be found in Table 1. Their
median age was 68 (i.q.r. 63–73) years; 106 (77⋅9 per
cent) were men and 30 (22⋅1 per cent) were women.
Twenty-three patients (16⋅9 per cent) had a good patho-
logical response to NAC (TRG 1–2); the Mandard TRG
groupings were: TRG1, 18 (13⋅2 per cent); TRG2, five
(3⋅7 per cent); TRG3, six (4⋅4 per cent); TRG4, 56 (41⋅2
per cent); andTRG5, 51 (37⋅5 per cent). During follow-up,
36 patients (26⋅5 per cent) developed cancer recurrence
and 69 (50⋅7 per cent) died. Median follow-up of survivors
was 27 (range 6–60) months. Around two-thirds of the
patients were followed up for at least 5 years or until death.
Baseline and area under the ROC curve (AUC) values
for markers of the systemic inflammatory response (SIR)
are shown in Table 2. The median value for NLR was 3⋅00
(i.q.r. 2⋅15–3⋅89). NLR was strongly associated with a
poorer Mandard TRG (AUC 0⋅71, 95 per cent c.i. 0⋅58
to 0⋅83; P = 0⋅002) (Fig. 1). Using the Youden index, the
optimal dichotomization threshold was 2⋅25, with 70⋅5
per cent considered to have a raised NLR. This gave
sensitivity and specificity values of 80⋅5 and 60⋅9 per cent
respectively. To adjust for potential confounding, a binary
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 416–423
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Table 5 Cox proportional hazards analysis of factors associated with disease-free survival
Univariable analysis Multivariable analysis
Hazard ratio P Hazard ratio P
Age (<65 versus 66–75 versus>75 years) 0⋅95 (0⋅59, 1⋅53) 0⋅823
Sex (F versus M) 1⋅08 (0⋅49, 2⋅38) 0⋅847
Operative approach (TTO versus THO) 2⋅64 (1⋅36, 5⋅11) 0⋅004 3⋅10 (1⋅58, 6⋅12) 0⋅001
Neutrophil to lymphocyte ratio (<2⋅25 versus≥2⋅25) 2⋅48 (1⋅08, 5⋅67) 0⋅032 0⋅288
pT category (0 versus 1 versus 2 versus 3 versus 4) 1⋅54 (1⋅09, 2⋅17) 0⋅014 1⋅72 (1⋅01, 2⋅93) 0⋅047
pN category (0 versus 1 versus 2 versus 3) 1⋅17 (0⋅98, 1⋅40) 0⋅081 0⋅091
Mandard TRG (good versus poor) 3⋅68 (1⋅12, 12⋅08) 0⋅032 0⋅936
Differentiation (well/moderate versus poor) 1⋅82 (0⋅94, 3⋅53) 0⋅078 0⋅372
CRM (negative versus positive) 1⋅38 (0⋅69, 2⋅74) 0⋅361
Lymph node yield (<15 versus≥15) 0⋅71 (0⋅37, 1⋅36) 0⋅302
Values in parentheses are 95 per cent confidence intervals. TTO, transthoracic oesophagectomy; THO, transhiatal oesophagectomy; TRG, tumour
regression grade; CRM, circumferential resection margin.
Fig. 2 Kaplan–Meier analysis of overall and disease-free survival in relation to neutrophil to lymphocyte ratio
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logistic regression model was developed to include the
clinical factors available to the MDT at the point of
commencing neoadjuvant therapy (Table 3).
The relationship between clinicopathological factors
and overall survival is shown in Table 4, and that between
clinicopathological factors and disease-free survival in
Table 5. Five-year overall survival rates for patients with a
low and high NLR were 50 and 20 per cent, respectively.
Five-year disease-free survival rates for low and high NLR
were 80 and 40 per cent, respectively.
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Discussion
The principal finding of this study is that a single biomarker
of SIR, a raised NLR, was a significant and indepen-
dent prognostic indicator of response to NAC before
potentially curative oesophagectomy for cancer. Based
on a dichotomization threshold of 2⋅25, 100 of the 136
patients (73⋅5 per cent) had a raised NLR, and were nearly
sixfold more likely to have a poor TRG response to NAC.
Median overall survival in patients with a low NLR was,
on average, 34months longer than that in patients with
a high NLR. Similarly, 5-year disease-free and overall
survival rates in patients with a low NLR were around 80
and 50 per cent respectively, approximately double those
of patients with a high NLR.
The relationship between the SIR and TRG in
oesophageal cancer has been described previously23,
in a study in which no association between NLR and
TRG was identified. Key differences in methodology from
that in the present study may account for these different
findings. The definition of good TRG response differed.
In the earlier study23, patients with TRG1–3 were con-
sidered good responders, whereas in the present study
TRG 1–2 was considered to represent a good response.
The OCCAMS research consortium currently favours the
TRG1–2 as indicative of good response5. The statistical
methods also differed. The earlier study23 looked only at
differences in NLR measurements between responders
and non-responders (2⋅26 versus 2⋅73; P = 0⋅127), but did
not examine the predictive value of NLR by ROC curve
or logistic regression analysis. Statistical nuances may, of
course, be overanalysed, but half of the TRG responders in
the earlier study had a NLR below 2⋅26, which implicitly
supports the critical threshold of 2⋅25 employed in the
present study. At the very least, markers of SIR require
further evaluation.
The prognostic power of SIR in relation to neoad-
juvant therapies has been reported previously, involving
rectal24,25, ovarian26, lung27 and breast28 cancers. A high
mGPS was associated with poor response to NAC in rec-
tal cancer (odds ratio (OR) 0⋅18, P = 0⋅006), and low NLR
was associated with a good pathological response (OR 0⋅27,
P = 0⋅046), although this did not retain independent signif-
icance in multivariable analysis24. Although other studies
have not specifically examined the role of SIR’s association
with pathological response to NAC, preoperative NLR has
been reported to predict overall survival, with high NLR
values being associated with poor survival29. Exactly why
SIR should be associated with poor response to neoadju-
vant chemotherapy in OAC is not understood, although
in vivo and in vitro evidence suggests that activation of the
JAK/STAT3 (Janus kinase/signal transducers and activators
of transcription) pathway by interleukin 6 may play a role
in chemoresistance30,31.
There are a number of inherent limitations to all studies
of this type, which have been reported previously7,32,33.
Cohort size was modest, and stage-by-stage subanalysis
was therefore impractical. The patients represented a
selected cohort (most had undergone a potentially curative
oesophagogastrectomy) and were consequently not repre-
sentative of all patients diagnosed with oesophageal cancer;
indeed, only about one-quarter of all patients in South
Wales with OAC undergo potentially curative surgery34.
The strengths of the study, nevertheless, included robust
follow-up data with no patient lost to follow-up, a rea-
sonable duration of follow-up, and accurate causes and
dates of death. A National Health Service laboratory using
standardized techniques performed the serum analyses
and histopathological examinations, so reproducing these
results should be easy. Patients were recruited from a
consecutive series diagnosed with OAC, from a single
UK geographical region, all treated by the same group
of specialists, using a standardized staging algorithm and
operative techniques, with internationally recognized and
published key performance indicators10.
Despite improvements in staging and surgical technique,
approximately half of the patients who undergo potentially
curative oesophagectomy for cancer will suffer disease
recurrence13,22. Determination of the NLR, derived and
calculated from absolute counts of serum lymphocytes
and neutrophils, is performed routinely during preop-
erative blood profile work, and is readily available. The
findings suggest that SIR offers a novel therapeutic target
for patients susceptible to NAC resistance and cancer
recurrence. Incorporation of the NLR into management
pathways is presently limited by inconsistent dichotomiza-
tion thresholds. Adequately powered studies comparing
critical dichotomization or categorization thresholds are
needed. Given the association between SIR and relative
chemoresistance, the identification of the group with high
NLR would suggest that these patients might benefit from
alternatives to NAC at the outset.
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